Compass Pathways’ COMP360 psilocybin therapy succeeded in two Phase 3 trials for treatment-resistant depression. Fast relief, lasting effects, and good safety profile – could be the first psilocybin medicine approved by FDA.
William Blair analyst upgrades Neumora Therapeutics to Outperform after strong early data for its Alzheimer's agitation drug NMRA-511, seeing big potential in a huge market.
Danaher Corporation announces a major $9.9 billion acquisition of Masimo, a leader in pulse oximetry and patient monitoring. The cash deal at $180 per share strengthens Danaher's diagnostics business and aims to improve patient care in hospitals.
Werewolf Therapeutics announces a 64% workforce reduction to save money, key executives leave with severance, and a new finance officer steps in as the company explores partnerships and funding options.
Disc Medicine's bitopertin gets turned down by FDA for treating EPP, a painful genetic condition making skin ultra-sensitive to sun.
Investment firm Craig-Hallum starts coverage on Compass Therapeutics with a Buy rating and $15 price target, highlighting its promising bispecific antibody pipeline and potential blockbuster in biliary tract cancer.
